• Friday, Dec 09, 2022
  • Last Update : 08:54 am

Sanofi, GSK launch trial for Covid-19 protein-based vaccine

  • Published at 02:49 am September 4th, 2020
Sanofi
File photo: The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24,2020 Reuters

The two companies are scaling up manufacturing in order to be ready to produce up to one billion doses in 2021 

French drugmaker Sanofi and Britain’s GlaxoSmithKline said they had started a clinical trial of their protein-based Covid-19 vaccine candidate, and aimed to reach the final testing stage by December. 

If the results are conclusive, Sanofi and GSK hope to get the vaccine approved in the first half of next year. 

The trial is currently in a “Phase 1/2 study” aimed at evaluating the safety, tolerability and immune response of the vaccine in 440 healthy adults across 11 investigational sites in the United States. 

The vaccine candidate uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines. It will be coupled with an adjuvant, a substance that acts as a booster to the vaccine, made by GSK. 

The two companies are scaling up manufacturing in order to be ready to produce up to one billion doses in 2021. 


Also read - White House slams WHO over criticism of push for Covid-19 vaccine


Drugmakers and government agencies worldwide are racing to develop vaccines and treatments for Covid-19, the illness caused by the new coronavirus, which has claimed more than 861,000 lives and crippled economic activity around the globe. 

Sanofi and GSK are not the first in the race - several vaccine candidates have already reached the final, wider testing stage known as “Phase 3” - but they believe their respective experience in the fields of vaccines is an advantage. 

The French group is also working on another vaccine candidate to prevent Covid-19 with US company Translate Bio which will rely on a different technology called mRNA. 

In an interview with Reuters last week, Sanofi’s CEO Paul Hudson said readings of preclinical data had increased the group’s confidence in its two coronavirus vaccine candidates. 

Sanofi and GSK have secured deals for the vaccine-plus-adjuvant with the United States and Britain, and are in advanced talks with the European Union to supply it with up to 300 million doses. 

They also plan to supply Covax, a Covid-19 vaccine and treatment allocation plan co-led by the World Health Organization (WHO) that aims to help buy and fairly distribute shots across the globe. 

Earlier this month, Sanofi said a rheumatoid arthritis drug, Kevzara, had failed as a Covid-19 treatment. 

50
Facebook 50
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail